Australian Gonococcal Surveillance Program, 1 July to 30 September 2025
Communicable Diseases Intelligence · 24.03.2026 · 50
DOI: 10.33321/cdi.2026.50.018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Communicable Diseases Intelligence, online erschienen am 24.03.2026. Verfasst von Monica Lahra und 3 weiteren Autor:innen. Beteiligte Einrichtung: NSW Health Pathology, The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, The Prince…. Hauptthemen laut MEDLINE: Gonorrhea, Neisseria gonorrhoeae, Anti-Bacterial Agents, Population Surveillance. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
The National Neisseria Network (NNN), Australia, established in 1979, comprises reference laboratories in each state and territory. Since 1981, the NNN has reported data for the Australian Gonococcal Surveillance Programme (AGSP), on antimicrobial susceptibility profiles for Neisseria gonorrhoeae isolated from each jurisdiction for an agreed group of agents. The antibiotics reported represent current or potential agents used for the treatment of gonorrhoea, and include ceftriaxone, azithromycin, ciprofloxacin and penicillin. More recently, gentamicin and tetracycline are included in the AGSP Annual Report. Ceftriaxone, combined with azithromycin, is the recommended treatment regimen for gonorrhoea in Australia. Historically, there were substantial geographic differences in susceptibility patterns across the country, with certain remote regions of the Northern Territory and Western Australia having low gonococcal antimicrobial resistance rates. In these regions, an oral treatment regimen comprising amoxycillin, probenecid, and azithromycin was recommended. However, since January 2023, increasing reports of penicillin-resistant N. gonorrhoeae in the Northern Territory have changed treatment recommendations to align with the majority of Australia.1 Additional data on other antibiotics are reported in the AGSP Annual Report. The AGSP is supported by a programme-specific quality assurance process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NSW Health Pathology, The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia; School of Medical S…
- NSW Health Pathology, The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology, The Prince of Wales Hospital, Randwick, NSW 2031, Australia.
- NSW Health Pathology, Molecular Microbiology, Royal Prince Alfred Hospital, Camperdown, NSW 2050, Australia.
Zitieren
APA
Lahra, M., Hurley, S., Van Hal, S., & Hogan, T. (2026). Australian Gonococcal Surveillance Program, 1 July to 30 September 2025. Communicable Diseases Intelligence, 50. https://doi.org/10.33321/cdi.2026.50.018
Vancouver
Lahra M, Hurley S, Van Hal S, Hogan T. Australian Gonococcal Surveillance Program, 1 July to 30 September 2025. Communicable Diseases Intelligence. 2026;50. doi:10.33321/cdi.2026.50.018
BibTeX
@article{Lahra2026,
author = {Lahra, Monica and Hurley, Siobhan and Van Hal, Sebastiaan and Hogan, Tiffany},
title = {Australian Gonococcal Surveillance Program, 1 July to 30 September 2025},
journal = {Communicable Diseases Intelligence},
year = {2026},
volume = {50},
doi = {10.33321/cdi.2026.50.018}
}
EUVIMED